Skip to main
ENTX

ENTX Stock Forecast & Price Target

ENTX Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Entera Bio is demonstrating great potential in the biopharmaceutical market by expanding their collaboration agreements and working on multiple promising drug candidates to address underserved medical conditions. With their focus on oral delivery, the company is creating convenient treatment options for patients and has shown successful results in their Phase 2 study for their EB612 program. The addition of Steve Rubin, a seasoned executive with experience in drug development, to the board of directors further strengthens Entera Bio's leadership team.

Bears say

Entera Bio is expected to enter the clinic soon with a next-generation formulation of EB613 that utilizes a refined version of its proprietary N-Tab formulation platform. Positive results from its Phase 1 trial could decrease pivotal clinical development risk and increase the commercial potential of this candidate. The pivotal program for EB613 is expected to begin later this year, with potential for regulatory approval and launch in 2029.

ENTX has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Entera Bio Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Entera Bio Ltd (ENTX) Forecast

Analysts have given ENTX a Strong Buy based on their latest research and market trends.

According to 1 analysts, ENTX has a Strong Buy consensus rating as of Jun 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Entera Bio Ltd (ENTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.